newswire, breaking biotechnology and pharma news

Wednesday, April 27, 2011

Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical (OTCBB: AEMD), ELI Lilly (LLY) Medtronic (MDT), Pfizer (PFE), (Apple (AAPL)

Point Roberts, WA- April 27,, a leader in sector stock research including
biotech/pharma stocks, reports on new trends in the healthcare sector where the industry is
reporting that medical technology is on the rise, and the development of new drugs may be
slowing down. The cost to bring a new drug to market, and the success rates may be a factor
in why some of the leading companies are looking at advancement in medical technology and

“In our case, we are leveraging our Hemopurifier® device to provide therapeutic capabilities
that target to improve infectious disease and cancer drug therapies,” stated Jim Joyce, CEO of
Aethlon Medical (OTCBB: AEMD).

Partnering technology to advance delivery of drugs is also a key to the future of healthcare. Eli
Lilly and Company (NYSE:LLY) and Medtronic, Inc. (NYSE:MDT) recently announced they have
entered into a collaboration to research and develop a new approach to treating Parkinson's
disease that involves delivering a potential new medicine to the brain using an implantable
drug delivery system. The goal of the collaboration is to develop a therapeutic approach for
Parkinson's disease that combines the strengths of Lilly's biologic, a modified form of glial
cell derived neurotrophic factor (GDNF), with Medtronic's implantable drug infusion system

As technology plays a key role in healthcare , new players enter the market from within the tech
sector including Apple’s (NasdaqGS: AAPL ) iPad, predicted to potentially revolutionize the
health-care universe.

Sector Snapshot
Aethlon Medical (OTCBB: AEMD) trading at $ 0.0911 - 0.10
Apple Inc.(NasdaqGS: AAPL ) trading at $348.69, down 1.73 (0.49%) 11:40AM EDT
Eli Lilly and Company (NYSE: LLY ) trading up at$ 37.10, up 0.28 (0.76%) 11:41AM EDT
Medtronic Inc.(NYSE: MDT ) trading at $41.38, up 0.14 (0.34%) 11:42AM EDT
Pfizer, Inc. Common Stock(NYSE: PFE ) trading at $20.44, up 0.25 (1.24%) 11:43AM EDT

Market Snapshot
Dow 12,609.68 +14.31 +0.11%
Nasdaq 2,847.00 -0.54 -0.02%
S&P 500 1,346.08 -1.16 -0.09%
10 Yr Bond(%) 3.3680% +0.0480
Oil 112.04 -0.17 -0.15%
Gold 1,508.50 +1.50 +0.10%

Recent article; Are Medical Devices the New Drugs?
Published: April 20, 2011

About Aethlon Medical (OTCBB: AEMD)
Visit the showcase profile at

Recent News:

About the Company:

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.
Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in
disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious
viruses and immunosuppressive proteins from the entire circulatory system. We recently
discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune
system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly
inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer
care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need
and provide the benefit of an immune-based therapy without adding drug toxicity or interaction
risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load
in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients
without the administration of antiviral drugs. However, our initial clinical and commercialization
focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both
infectious disease and cancer treatment regimens. In this regard, we plan to commercialize
our Hemopurifier® in India as we advance our clinical strategies in the United States and the
European Union. In vitro studies conducted by government and non-government research
institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against
bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue
Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1
Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus,
and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer
therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of
standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected
individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to
address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism
of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery
solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed
for implementation within the established infrastructure of dialysis machines and other blood
circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that
tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer
and glycoproteins residing on the envelope of viruses. These agents are immobilized around
approximately 2800 porous hollow fibers that run the interior length of our device. The resulting
design provides us the novel ability to separate both exosome and viral targets away from blood
cells so they can then be selectively and permanently removed from the circulatory system. In
application, blood circulation is established into the Hemopurifier® via a catheter or other blood
access device. Once blood flow has been established, treatment benefit is immediate as the
entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of
exosome-targeted products and services that improve cancer diagnosis, provide post-treatment
cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient

therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be
accessed online at

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking
statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of
the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as
cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease
conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of
its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products either internally or through outside companies and provide
its services, the impact of government regulations, patent protection on the Company's proprietary technology, product
liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety of factors, including the risks associated with
the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange
Commission filings.

James A. Joyce
Chairman, CEO
858.459.7800 x301

About is a leading global investor and industry research resource portal specialized in sector
investing, including biotech stocks with its portal

Research more biotech stocks at the Biotech stocks Directory:

Visit the showcase page on

Get added to the company’s news alerts:

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make

recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on
our sites should be construed as an offer or solicitation to buy or sell products or securities. All showcase company
info is obtained from public filings, news, or directly from management. This site is currently compensated by featured
companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase
biotech, biodefense and defense stock on ( $one thousand five hundred per month, $five thousand per
month in 144 stock)Effective March 15, 2011

800-665-0411 - Source -

No comments:

Post a Comment